Founded Year

2014

Stage

Series F | Alive

Total Raised

$1.353B

Last Raised

$254M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

-13 points in the past 30 days

About Freenome

Freenome operates as a biotechnology company specializing in early cancer detection within the healthcare sector. The company develops blood tests that use multiomics technology and artificial intelligence to identify cancer at its earliest and most treatable stages. It was founded in 2014 and is based in Brisbane, California.

Headquarters Location

3300 Marina Boulevard 5th Floor

Brisbane, California, 94005,

United States

650-446-6630

Loading...

ESPs containing Freenome

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…

Freenome named as Challenger among 15 other companies, including Roche, Becton Dickinson, and Exact Sciences.

Loading...

Research containing Freenome

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Freenome in 7 CB Insights research briefs, most recently on Jan 16, 2025.

Expert Collections containing Freenome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Freenome is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,297 items

A

AI 100 (All Winners 2018-2025)

99 items

Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

D

Digital Health 50

300 items

The most promising digital health startups transforming the healthcare industry

D

Digital Health

12,122 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Freenome Patents

Freenome has filed 22 patents.

The 3 most popular patent topics include:

  • molecular biology
  • oncology
  • cancer screening
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2023

3/11/2025

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Grant

Application Date

8/18/2023

Grant Date

3/11/2025

Title

Related Topics

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Status

Grant

Latest Freenome News

Global Deep Learning In Diagnostics Market to Reach $11.84 Billion at a Steady 35.8% CAGR by 2029

Oct 10, 2025

Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, October 10, 2025 / EINPresswire.com / -- How Large Will The Deep Learning In Diagnostics Market Be By 2025? The application of deep learning in the field of diagnostics has seen rapid expansion in terms of its market size in recent times. The value of this market, which is projected to increase from $2.56 billion in 2024 to $3.49 billion in 2025, corresponds to a compound annual growth rate (CAGR) of 36.1%. Several factors have played a part in this growth in the historic period, including an increase in the amount of healthcare information available due to digital health records, a surge in the use of cloud-based diagnostic technologies, the need for quicker diagnostic results, the rising demand for affordable diagnostic alternatives in developing areas, and the increased utilization of deep learning in genomics and precision diagnostics. The market size of deep learning in diagnostics is predicted to experience substantial expansion in the coming years, escalating to $11.85 billion in 2029 at a compound annual growth rate (CAGR) of 35.8%. This anticipated growth during the forecast period can be attributed to factors such as rising demand for early and precise detection of diseases, increased prevalence of chronic and lifestyle-related conditions, bolstered investment in artificial intelligence research and development within healthcare, a burgeoning need to lower diagnostic errors whilst enhancing accuracy, and increased implementation of digital pathology and radiology solutions. Significant market trends expected in the forecast period include advancements in AI-integrated 3D imaging, incorporation of AI with electronic health records, progress in predictive analytics for disease identification, fusion of AI with genomic and multi-omics data, and novel developments in automated image interpretation. Download a free sample of the deep learning in diagnostics market report https://www.thebusinessresearchcompany.com/sample.aspx?id=28190&type=smp What Are The Major Driving Forces Influencing The Deep Learning In Diagnostics Market Landscape? The surge in healthcare digitalization is predicted to fuel the expansion of the deep learning in diagnostics market. Healthcare digitalization implies the integration of digital solutions into healthcare systems to improve effectiveness, accessibility, data control, and overall patient service quality. The escalation in healthcare digitalization is triggered by its capacity to guarantee successful management and safe transfer of rapidly increasing quantities of patient information, fostering better care collaboration and educated decision-making. The digital transformation of healthcare generates vast quantities of data from medical imaging, electronic health records, and connected devices. This creates a demand for deep learning in diagnostics, as it can competently scrutinize this data and provide quicker, more precise insights than conventional methods. For example, in June 2022, The Department of Health and Social Care, a UK government entity, reported that by March 2025, all NHS trusts are anticipated to have introduced electronic health records, an increase from 90% adoption by December 2023. As such, the surge in healthcare digitalization is steering the expansion of the deep learning in diagnostics market. Who Are The Top Players In The Deep Learning In Diagnostics Market? Major players in the Deep Learning In Diagnostics Global Market Report 2025 include: • International Business Machines Corporation • Siemens Healthineers AG • Koninklijke Philips N.V. • GE HealthCare Technologies Inc. • Tempus AI Inc. • Qure.ai Technologies Pvt. Ltd. • Freenome Holdings Inc. • PathAI Inc. • Aidoc Medical Ltd. • Viz.ai Inc. What Are The Top Trends In The Deep Learning In Diagnostics Industry? Leaders in the diagnostics market that leverage deep learning are honing in on the creation of innovative solutions, including those propelled by AI, to secure more precise diagnoses, expedite diagnostic processes, and offer more customized care to patients. An AI-led deep learning system is a sophisticated system that employs artificial intelligence and multilayered neural networks to autonomously analyze intricate medical data, decipher patterns, and generate highly precise diagnostic insights, minimizing the need for extensive human input. For instance, in May 2025, GE Healthcare Technologies Inc., a medical technology and diagnostics firm based in the U.S., presented CleaRecon DL, a solution specifically designed to advance image reconstruction and enhance diagnostic precision. This tool improves cone-beam CT (CBCT) imaging by effectively eliminating streak distortions, thereby delivering clearer and more accurate visuals for interventional procedures. The technology bolsters the confidence of clinicians in interpreting images and improves accuracy during interventions, as demonstrated by clinical trials that showed a 98% improvement in image clarity and 94% increased confidence. Ultimately, this leads to improved patient results by optimizing workflow and facilitating more effective, image-guided treatments. Market Share And Forecast By Segment In The Global Deep Learning In Diagnostics Market The deep learning in diagnostics market covered in this report is segmented as 1) By Component: Software, Hardware, Services 2) By Deployment Mode: Cloud-Based, On-Premises 3) By Application: Medical Imaging, Pathology, Genomics, Drug Discovery, Other Applications 4) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users Subsegments: 1) By Software: Diagnostic Imaging Software, Pathology Analysis Software, Genomic Data Analysis Software 2) By Hardware: Storage Devices, Networking Devices, Diagnostic Imaging Equipment 3) By Services: Deployment And Integration Services, Training And Education Services, Consulting Services View the full deep learning in diagnostics market report: https://www.thebusinessresearchcompany.com/report/deep-learning-in-diagnostics-global-market-report Deep Learning In Diagnostics Market Regional Insights In the Deep Learning In Diagnostics Global Market Report 2025, North America emerged as the dominant region in 2024. The region projected to experience the swiftest growth is Asia-Pacific. The report encompasses various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse Through More Reports Similar to the Global Deep Learning In Diagnostics Market 2025, By The Business Research Company Clinical Trial Management Systems Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/clinical-trial-management-systems-global-market-report Virtual Clinical Trials Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report Clinical Trial Management System Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/clinical-trial-management-system-global-market-report Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: saumyas@tbrc.info The Business Research Company - www.thebusinessresearchcompany.com Follow Us On: • LinkedIn: https://in.linkedin.com/company/the-business-research-company Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Freenome Frequently Asked Questions (FAQ)

  • When was Freenome founded?

    Freenome was founded in 2014.

  • Where is Freenome's headquarters?

    Freenome's headquarters is located at 3300 Marina Boulevard, Brisbane.

  • What is Freenome's latest funding round?

    Freenome's latest funding round is Series F.

  • How much did Freenome raise?

    Freenome raised a total of $1.353B.

  • Who are the investors of Freenome?

    Investors of Freenome include DCVC, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Section 32 and 54 more.

  • Who are Freenome's competitors?

    Competitors of Freenome include Owlstone Medical, 20/20 BioLabs, BioTwin, GRAIL, Diagu and 7 more.

Loading...

Compare Freenome to Competitors

20/20 BioLabs Logo
20/20 BioLabs

20/20 BioLabs provides diagnostics for the healthcare sector, focusing on the detection and prevention of cancers and chronic diseases. The company offers laboratory-based blood tests that utilize machine learning algorithms to analyze real-world data, providing testing solutions. It serves individuals seeking health management and healthcare providers in need of diagnostic tools. 20/20 BioLabs was formerly known as 20/20 GeneSystems. It was founded in 2000 and is based in Gaithersburg, Maryland.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.

O
OncoTAB

OncoTAb specializes in biotechnology with a focus on cancer diagnostic solutions. The company offers Agkura® Personal Score, a non-invasive blood test that measures tumor protein levels to aid in breast cancer detection. This test serves as a supplemental tool to mammography, which often misses cancers in women with dense breast tissue. It is based in Charlotte, North Carolina.

Accuragen Logo
Accuragen

AccuraGen develops liquid biopsy technology for the cancer diagnostics industry. The company provides services related to DNA and RNA sequencing to assist in treatment plans for cancer patients, emphasizing non-invasive diagnostic methods. AccuraGen serves the healthcare sector, particularly in oncology. It is based in Menlo Park, California.

L
Liquid Genomics

Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.

A
Artificial Intelligence Expert

Artificial Intelligence Expert focuses on AI technologies related to early detection of cancer within the healthcare sector. The company provides tests that can identify various types of cancer with reported accuracy rates. It is based in Cluj-Napoca, Romania.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.